false
0001763950
0001763950
2024-11-07
2024-11-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 7, 2024
Lantern
Pharma Inc.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39318 |
|
46-3973463 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
1920
McKinney Avenue, 7th Floor
Dallas,
Texas |
|
75201 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
(972)
277-1136
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, $0.0001 par value |
|
LTRN |
|
The
Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
November 7, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the
third quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
The
information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Lantern
Pharma Inc., |
| |
A
Delaware Corporation |
| |
|
| Dated:
November 7, 2024 |
By: |
/s/
David R. Margrave |
| |
|
David
R. Margrave, Chief Financial Officer |
Exhibit
99.1
Lantern
Pharma Reports Third Quarter 2024 Financial Results and Business Updates
| ■ | Lantern
is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase
2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. |
| ■ | Preliminary
patient data and clinical readouts for the Phase 2 LP-300 Harmonic™ Trial showed
an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients
continue to be enrolled in the US. |
| ■ | The
Harmonic™ Trial has been expanded to both Japan and Taiwan with an expected
10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35
percent of new cases in NSCLC. |
| ■ | Phase
1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284,
continue to advance with no dose-limiting toxicities observed in any of the patient cohorts
enrolled and over 50 patients dosed to-date across both trials. |
| ■ | LP-184,
which will be developed as STAR-001 for CNS and other neuro-oncology indications,
received Fast Track Designation in Glioblastoma (GBM) from the FDA. |
| ■ | Patients
with recurrent GBM have been enrolled in the LP-184 Phase 1a trial at 2 academic centers,
including Johns Hopkins, and 1 community site; the data will help guide later stage clinical
development planned to be sponsored by Starlight Therapeutics during early 2025. |
| ■ | Biomarker
analysis for PTGR1 expression using qPCR for the first 7 cohorts of patients enrolled
in the Phase 1a LP-184 clinical trial has begun, and will help guide the advancement
of PTGR1 as a key RNA biomarker that can guide patient response prediction. |
| ■ | Three
U.S. FDA Rare Pediatric Disease Designations were granted to LP-184 in three
ultra rare children’s cancers. |
| ■ | Three
scientific publications in Q3 including: a peer-reviewed paper regarding the unique AI-powered
module for ADC development as part of the RADR® platform; and findings presented
at conferences regarding the ongoing development of Lantern’s synthetically-lethal
drug candidates at the Immuno-Oncology Summit for LP-184 and The Society of Hematologic Oncology
for LP-284. |
| ■ | Approximately
$28.1 million in cash, cash equivalents, and marketable securities as of September
30, 2024. |
| ■ | The
conference call and webcast are scheduled for Thursday, November 7, 2024 at 4:30 p.m.
ET. |
Thursday,
November 7, 2024
DALLAS—
(Business Wire) — Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted
and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with
multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending
September 30, 2024.
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
1
|
“Lantern
is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on the initial positive results from
our Harmonic™ trial in both the US and Asia, we are also advancing our RADR® AI platform to strategically guide
our therapeutic pipeline. The emerging combination therapy opportunities we are identifying for both LP-184 and LP-284 underscore the
strength of our AI-guided approach. Seeing our drug candidates advance in clinical trials, with the potential to meaningfully impact
cancer patients’ lives, reinforces our mission. Additionally, as Starlight Therapeutics enters its next chapter of growth
in CNS cancers, we look ahead to our plans for a Phase1b/2 clinical trial for STAR-001. We remain focused on the objective of developing
therapies—at a fraction of the cost and time of traditional drug development by using our AI platform and data-driven methodologies.
Our goal is ultimately to address critical and often unmet patient needs in oncology,” said Panna Sharma, President and CEO of
Lantern Pharma.
Highlights
of AI-Powered Pipeline:
| ● | LP-300:
The Harmonic™ Phase 2 Clinical Trial – The Phase 2 Harmonic™ trial
is aimed at making a significant advancement in addressing an urgent unmet need for never-smoker
patients with non-small cell lung cancer (NSCLC). In the initial safety lead-in cohort of
7 patients, LP-300 demonstrated encouraging preliminary results when combined with
standard-of-care chemotherapy (pemetrexed and carboplatin), achieving an 86% clinical benefit
rate and a 43% objective response rate. Of particular note, 3 patients achieved partial responses
with an average tumor size reduction of 51%, while 3 additional patients achieved stable
disease with an average tumor reduction of 13%. Importantly, these preliminary results were
observed regardless of prior tyrosine kinase inhibitor (TKI) treatments, patient demographics,
or metastatic disease sites, suggesting broad potential applicability across the never-smoker
NSCLC population. |
The
trial’s safety profile has been especially promising, with no dose-limiting toxicities observed and no discontinuations due to
LP-300 treatment-related toxicity. The most common adverse events were manageable decreases in white blood cell count and thrombocytopenia.
The
Harmonic™ trial has now progressed to its randomization and expansion phase, which is designed to enroll up to an additional
84 patients in a 2:1 ratio comparing LP-300 plus standard-of-care chemotherapy versus chemotherapy alone. With regulatory approval to
expand into multiple Asian countries, the trial is positioned to accelerate enrollment in the targeted patient population of never-smokers
with NSCLC, which we believe represents a potential global market estimated at over $4 billion annually. Leading our Harmonic™
trial efforts in Japan is Dr. Yasushi Goto, a renowned physician and researcher at the National Cancer Center Japan, where the
incidence of never-smoker NSCLC is more than double that of the United States. The company has also initiated five trial sites in Taiwan,
where over 40% of the new lung cancer diagnoses are among never-smokers, strategically positioning the Harmonic™ trial in regions
with the highest prevalence of the target patient population. Lantern believes that this improves the potential for drug-candidate LP-300
to develop collaboration and co-development partnerships with global biopharma companies with a primary focus in serving the Asian markets.
The study’s co-primary endpoints are progression-free survival (PFS) and overall survival (OS), with planned interim analysis after
31 patients have experienced disease progression which is expected by mid 2025.
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
2
|
| ● | LP-184
– LP-184 continues to advance through its Phase 1a first-in-human basket trial
(NCT05933265) across multiple solid tumor indications. Nine patient cohorts have been successfully
dosed at escalating dose levels, and no dose-limiting toxicities observed to date. The trial
is actively enrolling patients with relapsed/refractory advanced solid tumors, including
pancreatic cancer, glioblastoma (GBM), triple-negative breast cancer, and other solid tumor
types with DNA damage response deficiencies. Based on pharmacokinetic analyses, the upcoming
cohorts are expected to reach dosage levels where therapeutic concentrations should be attainable,
with enrollment projected to complete this year and initial safety and molecular correlation
data expected by year-end 2024 or early 2025. |
The
LP-184 development program received a significant boost with the FDA granting Fast Track Designation in glioblastoma, recognizing both
the serious nature of GBM and the significant unmet medical need in this indication which affects more than 13,000 U.S. adults annually.
Through Lantern’s wholly-owned subsidiary Starlight Therapeutics, LP-184 (designated as STAR-001 for CNS indications) is being
positioned for a Phase 1b/2a clinical trial in recurrent GBM that is targeted to begin in early 2025. Lantern has also made important
progress towards developing a quantitative PCR-based molecular diagnostic test that could help identify patients most likely to respond
to LP-184 treatment. Lantern is in the process of validating the PCR assay with patient samples from the initial seven cohorts from the
LP-184 Phase 1a trial and we plan on using the molecular correlations to power future development and trial design.
Additional
ongoing preclinical studies continue to demonstrate LP-184’s potential, particularly in combination therapy settings with some
of the most widely used FDA approved drugs. One of these combinations using an FDA approved agent, spironolactone, is directed at the
treatment of GBM and will be part of the planned Phase 1b study. Recent data presented at scientific conferences has highlighted promising
synergy when LP-184 is combined with various FDA-approved treatments, including PARP inhibitors and immune checkpoint inhibitors. LP-184
has also shown promise in cancers with DNA damage response deficiencies beyond deficiencies in homologous recombination repair, demonstrating
synthetic lethality in indications beyond those traditionally considered for PARP inhibitors. With an estimated aggregate annual market
potential of approximately $12+ billion across its target indications ($4.5+ billion for CNS cancers and $7.5+ billion for solid tumors),
we believe LP-184 represents a significant commercial opportunity while potentially addressing critical unmet patient needs across multiple
cancer types.
| ● | LP-284
– The fourth cohort of patients are being dosed, and no dose-limiting toxicities
have been observed in the LP-284 Phase 1a clinical trial. We are in the process of opening
additional hematology-focused sites later this year, with the potential to advance to Phase
1b or 2 by early to mid 2025. LP-284 has shown nanomolar potency across multiple published
in vitro and in vivo studies, including mantle cell lymphoma (MCL), double hit lymphoma (DHL),
and other advanced NHL cancer subtypes with DNA damage response deficiencies, notably those
with compromised functioning of the ataxia-telangiectasia mutated (ATM) gene due to mutations
or deletions. Nearly all MCL, DHL, and HGBL patients relapse from the current standard-of-care
agents and there is an urgent and unmet need for novel improved therapeutic options for these
patients. In the US and Europe, MCL, DHL, and HGBLs are diagnosed in 16,000-20,000 patients
each year and these indications represent an estimated annual market potential of over $3+
billion. |
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
3
|
Third
Quarter 2024 Financial Highlights
| ● | Balance
Sheet: Cash, cash equivalents, and marketable securities were approximately $28.1 million
as of September 30, 2024, compared to approximately $41.3 million as of December 31, 2023.
The quarterly cash burn rate continues to reflect our capital-efficient, collaborator-centered
business model. |
| ● | R&D
Expenses: Research and development expenses were approximately $3.7 million for the quarter
ended September 30, 2024, compared to approximately $2.2 million for the quarter ended September
30, 2023. |
| ● | G&A
Expenses: General and administrative expenses were approximately $1.5 million for the
quarter ended September 30, 2024, compared to approximately $1.3 million for the quarter
ended September 30, 2023. |
| ● | Net
Loss: Net loss was approximately $4.5 million (or $0.42 per share) for the quarter ended
September 30, 2024, compared to a net loss of approximately $3.2 million (or $0.29 per share)
for the quarter ended September 30, 2023. |
| ● | Total
Share and Warrant Count: During the three months ended September 30, 2024, the Company
issued 2,088 shares of common stock relating to the cashless exercise of warrants to purchase
7,664 shares, which warrants were expiring. Also during the three months ended September
30, 2024, the Company issued 3,832 shares of common stock for aggregate proceeds of $11,994
relating to the exercise of warrants that were expiring. As of the date of this press release,
the Company has 10,784,725 shares of common stock outstanding, and outstanding warrants to
purchase 70,000 shares of common stock. |
Additional
Operational Highlights:
| ● | Lantern
is building an efficient internal clinical operations team that it is leveraging across a
range of clinical activities, from project management to site startup through data and quality
management, and as a result is expected to rely less on external CRO providers with the aim
of further managing ongoing clinical trial costs. |
| ● | Lantern
published new research in PLOS ONE highlighting its data-driven approach to ADC design and
development. The publication, titled ‘Expanding the repertoire of Antibody Drug
Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through
in-silico analysis,’ demonstrates a multi-step filtering approach to identify optimal
ADC targets and payloads. Starting with over 20,000 protein-coding genes, they systematically
narrowed candidates using membrane protein status, expression levels in critical tissues,
and surface protein validation. The study uniquely analyzed how 416 different mutations across
22 tumor types affect target expression, revealing how specific mutations like KRAS in pancreatic
cancer and EGFR in gliomas influence target levels. The analysis identified 82 promising
ADC targets and 729 potential payloads, including novel candidates and repurposing opportunities
for existing compounds with picomolar to nanomolar potency. We believe this comprehensive
approach provides a framework for developing more precise and effective ADC therapeutics
and assessing the utility and viability of an ADC design earlier in the development process. |
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
4
|
| ● | New
data and scientific findings conducted in conjunction with Drs. Yong Du and Shiaw-Yih
(Phoebus) Lin at MD Anderson were presented at The Immuno-Oncology Summit 2024.
The findings showcased what Lantern believes to be the role of LP-184 to be combined with
checkpoint inhibitors to provide greater response in TNBC due to synergy and to potentially
transform TNBC tumors that are unresponsive (cold) to checkpoint inhibitors to responsive
(hot). The poster was titled: LP-184, a Novel Acylfulvene, Sensitizes Immuno-Refractory
Triple Negative Breast Cancers (TNBCs) To Anti-PD1 Therapy by Affecting the Tumor Microenvironment. |
| ● | Lantern
will host its final Webinar Wednesday of 2024 on December 11, 2024, focusing on the
company’s unique ability to predict blood-brain barrier penetration of drug compounds.
The webinar will also discuss future development plans and potential commercial availability
of this RADR® platform module, which leverages extensive molecular feature
analysis enriched with proprietary insights and data. According to the Therapeutic Data
Commons, a coordinated initiative to access and evaluate artificial intelligence capability
across therapeutic modalities and stages of discovery, Lantern’s BBB algorithms are
5 of the top 10 performing algorithms on the “Leaderboard”. |
Earnings
Call and Webinar Details:
Lantern will host its 3rd quarter 2024 earnings call and webinar today, November 7th, 2024, at 4:30 p.m. ET.
A link to register can be accessed at: (LTRN: 3rd Quarter Earnings Call & Zoom link)
| ● | Related
presentation materials will be accessible at: https://ir.lanternpharma.com |
| ● | A
replay of the 3rd quarter 2024 earnings call and webinar will be available at:
https://ir.lanternpharma.com |
ABOUT
LANTERN PHARMA
Lantern
Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary
AI and machine learning (ML) platform, RADR®, leverages billions of oncology-focused data points and a library of 200+
advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI
and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of
therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program.
On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years
and at approximately $1.0 - 2.5 million per program.
Our
lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned
subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers,
many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined
annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of
cancer patients across the world.
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
5
|
CONTACT:
Investor
Relations
ir@lanternpharma.com
(972)277-1136
Please
find more information at:
| ● | Website:
www.lanternpharma.com |
| ● | LinkedIn:
https://www.linkedin.com/company/lanternpharma/ |
| ● | X:
@lanternpharma |
FORWARD
LOOKING STATEMENT:
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating
to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug
candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of
our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates
and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development
efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development
process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk
and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our
plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves
or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements
that use words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “target,” “model,” “objective,” “aim,”
“upcoming,” “should,” “will,” “would,” or the negative of these words or other similar
expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results
to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research
of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations
in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that
we may not be able to secure sufficient future funding when needed and as required to advance and support existing and planned clinical
trials and operations, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships
and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully
initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug
product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated
into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for
the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report
on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or
on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking
statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements
will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this
press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update
any forward-looking statements to conform the statement to actual results or changes in our expectations.
Lantern
Pharma Disclosure Channels to Disseminate Information:
Lantern
Pharma’s investors and others should note that we announce material information to the public about our company and its technologies,
clinical developments, licensing matters and other matters through a variety of means, including Lantern Pharma’s website, press
releases, SEC filings, digital newsletters, and social media, in order to achieve broad, non-exclusionary distribution of information
to the public. We encourage our investors and others to review the information we make public in the locations above as such information
could be deemed to be material information. Please note that this list may be updated from time to time.
###
| www.lanternpharma.com |
Q3
2024 Lantern Pharma Earnings Press Release & Update |
pp.
6
|
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Lantern Pharma (NASDAQ:LTRN)
過去 株価チャート
から 11 2024 まで 12 2024
Lantern Pharma (NASDAQ:LTRN)
過去 株価チャート
から 12 2023 まで 12 2024
